['hiv-1 infection']
['dolutegravir 50 mg', 'tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg', 'efavirenz 200 mg']

        Inclusion Criteria:

          -  HIV-1 infected

          -  Age ≥ 18 years

          -  Abtiretroviral-naïve, including above 7 days of cumulative prior antiretroviral
             therapy at any time prior to study entry.

          -  For women of childbearing potential: acceptance to use effective contraceptive methods

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Infection with HIV-1 group O, N, P

          -  Infection or co-infection with HIV-2

          -  Absolute neutrophil count (ANC) < 500 cells/mm3

          -  Hemoglobin < 7.0 g/dL

          -  Platelet count < 50,000 cells/mm3

          -  AST and/or ALT > 5 x Upper Limit of Normal (ULN)

          -  Calculated creatinine clearance < 50 mL/min

          -  Active opportunistic or severe disease not under adequate control

          -  For women of childbearing age : Pregnancy/breastfeeding

          -  History or presence of allergy and/or contraindications to the trial drugs or their
             components

          -  Severe psychiatric illness

          -  Severe hepatic failure Patients co-infected with tuberculosis (TB), receiving a TB
             treatment and with stable clinical condition will not be excluded.
      